通阳降逆汤干预未成熟型疣状胃炎疗效观察

Clinical observation of Tongyangjiangni formulae in intervene of immature verrucosa gastritis

目的:探讨中西医结合治疗未成熟型疣状胃炎临床疗效。方法:将90例幽门螺杆菌(H.pylori)阳性未成熟型的疣状胃炎患者随机分为两组,每组45例。根除H.pylori治疗1周后,治疗组予通阳降逆汤治疗3周,对照组予泮托拉唑治疗3周。治疗1个月后评价症状、胃镜改善和H.pylori根除情况,显效者随访至6个月。结果:两组治疗后症状缓解和胃镜下黏膜改善情况比较,治疗组治疗后积分(8.12±2.25)与对照组治疗后积分(12.12±1.90)比较差异具有显著性(P<0.05);治疗组治疗前后相比,差异具有显著性(P<0.01);两组治疗后H.pylori根除率比较,治疗组88.9%,对照组77.8%,根除率差异有统计学意义(P<0.05);两组临床疗效比较有显著性差异,总有效率(P<0.05)。38例显效者随访6个月复发率,治疗组9.1%,对照组12.5%,两者复发率比较有显著性差异(P<0.05)。结论:通阳降逆汤干预治疗未成熟型疣状胃炎有效、安全、便宜、复发率低。

Objective： To observe the effect of traditional Chinese medicine combined western medicine to treat the immature verrucosa gastritis. Methods： Totally 90 patients who were diagnosed as immature verrucosa gastritis in H.pylori-positive through endoscopy and conducted biopsy, while patients were detected helicobacter pylori using 14C urea breath test. 90 cases were randomly divided into treatment group and control group, with 45 cases for each group. First, each group received helicobactoer pylori eradication for lweek; then the treatment group received the therapy of Tongyangjiangni formulae for 3 weeks, while the control group received pantoprazole for 3 weeks. The course of treatment lasted for a month, estimated of clinical symptoms, endoscopic manifestations and eradication rate of helicobactoer pylori. Total effective patients were followed up 6 months. Results： There was a significant difference （8.12_＋2.25 vs 12.12_＋1.98, P〈0.05） in the scoles afcer treatment of clinical symptoms and endoscopic manifestations between treatment group and control group. Comparing the two groups after treatment, eradication rate of helicobactoer pylori was a significant difference （88.9% vs 77.8%, P〈0.05） and the relapse rate in the treatment group was lower than the control group （9.1% vs 12.5%, P〈0.05）. Conclusion： The adoption of Tongyangjiangni formulae combined with helicobactoer pylori eradication treating the immature verrucosa gastritis is effective, safe, and cheap and with lower recurrence rate.